Drugs / TARGTEPO
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02468414 | Jun 2015 → May 2016 | anemia due to chronic disorder | Aevi Genomic Medicine, LLC, a Cerecor company | Terminated | No outcome recorded |
| Phase 2 | NCT02378662 | Apr 2015 → Jan 2016 | anemia due to chronic disorder | Aevi Genomic Medicine, LLC, a Cerecor company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TARGTEPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02468414 ↗ |
| Known as | MDGN201 | “MDGN201 TARGTEPO secreting EPO” NCT02468414 ↗1“MDGN201 TARGTEPO secreting EPO” NCT02378662 ↗ |